Introduction
============

Fatigue is a common symptom in cancer patients. The rate of metastatic cancer patients with cancer-related fatigue (CRF) is \>75%, and cancer survivors report that, even if their condition improves after treatment, fatigue often persists for months or even years. Cancer patients state that fatigue is one of the most distressing symptoms associated with cancer, and the general condition during cancer treatment is difficult to manage with medications ([@b1-mco-0-0-1557]).

The pathophysiology of fatigue in cancer patients is multifactorial. Suggested mechanisms include an imbalance in energy metabolism due to tumor growth, infection, fever, or surgery, malnutrition caused by anorexia, nausea, or vomiting, and an increase in the abnormal production of substances that impair metabolic homeostasis, such as cytokines and proteolysis-inducing factors ([@b2-mco-0-0-1557]). Other researchers have suggested mechanisms that link fatigue to the pathophysiology of sleep disorders, major depression anemia, or hypoxia. However, there is no conclusive evidence to support the application of specific methods to reduce fatigue in cancer patients; thus, further investigation is required ([@b1-mco-0-0-1557]).

Carnitine, a micronutrient derived from an amino acid, is found in almost all cells of the body, and it plays an important role in energy metabolism ([@b3-mco-0-0-1557]). Long-chain fatty acids are transported by carnitine across the membranes of mitochondria in muscle cells, and β-oxidation converts fatty acids into energy in the form of adenosine triphosphate. Additionally, carnitine also transports fatty acids out of the mitochondria ([@b3-mco-0-0-1557]). Carnitine reabsorption is regulated through the proximal tubules of the kidney. Skeletal and cardiac muscles use fatty acids as their primary source of energy; thus, carnitine deficiency is associated with low energy levels and muscle weakness ([@b4-mco-0-0-1557]).

Carnitine homeostasis is regulated by oral intake, synthesis and renal reabsorption. In humans, carnitine is produced in the liver and kidneys, stored in skeletal muscle and excreted in the urine. Certain cytotoxic chemotherapies interfere with the homeostasis and reabsorption of carnitine ([@b5-mco-0-0-1557]--[@b7-mco-0-0-1557]). Nausea, vomiting and anorexia caused by cancer treatment may reduce the oral intake of food, which may lead to low plasma levels of carnitine ([@b8-mco-0-0-1557]).

Recent studies demonstrated that L-carnitine (LC) supplementation in patients with cancer was effective in reducing fatigue ([@b4-mco-0-0-1557],[@b5-mco-0-0-1557]) and increasing the lean body mass and appetite ([@b9-mco-0-0-1557]). However, the type of patients who may benefit from LC supplementation has not been fully elucidated. The aim of the present study was to monitor fatigue in cancer patients who received chemotherapy, adjuvant chemotherapy or treatment for metastatic disease, and to evaluate changes in fatigue prior to and following LC supplementation.

Patients and methods
====================

### Patients

The present study was performed with the approval of the Internal Review Board on ethical issues of Hokkaido Social Work Association Obihiro Hospital. A total of 11 patients who underwent chemotherapy in our hospital between September 2014 and December 2015 and experienced fatigue during chemotherapy were retrospectively reviewed. The inclusion criteria were as follows: i) Pathological diagnosis of cancer; ii) the patients must have been informed of their cancer diagnosis; iii) administration of at least one cycle of a chemotherapeutic regimen; iv) Eastern Cooperative Oncology Group performance status of 0 or 1; v) the patients had to be able to understand and complete the questionnaires; and vi) no severe mental or cognitive disorders.

### Fatigue measurements

The Brief Fatigue Inventory (BFI) was selected to assess fatigue, as it is a multidimensional, independent, commonly used scale for the clinical assessment of fatigue. The BFI consists of 9 items, using a numerical scale of 0--10 on a single page. The global score for the BFI is calculated as the mean value of these 9 items and categorized as follows: Scores of 1--3, mild; scores of 4--6, moderate; and scores of 7--10, severe ([@b10-mco-0-0-1557],[@b11-mco-0-0-1557]).

### Treatment plan with LC

Based on the current knowledge on carnitine use, its metabolism, and treatment of deficiency, a daily oral dose of 1.5 g LC divided into in three single doses of 0.5 g was administered for 8 weeks, preferably during or following meals.

### Study design

The enrolled patients were evaluated for fatigue at the baseline and after 2 weeks of LC supplementation. Following baseline evaluation, the patients started treatment with 1.5 g of oral LC three times daily for 8 weeks. During treatment, the patients were monitored every 2 weeks with physical examination, medical history and blood chemistry tests. The patients were stratified into two categories according to chemotherapy, namely the adjuvant chemotherapy (Adj.) and unresectable or recurrence (Rec.) groups.

### Statistical analysis

The patient records were entered into our database and completed with information obtained from a retrospective review of hospital and physician records. Statistical analysis was performed using the JMP 13.0.0 software package (SAS Institute, Inc., Tokyo, Japan).

Results
=======

### Patient demographics and tumor characteristics

The mean patient age was 67.5 years \[standard deviation (SD) ±7.3 years\]. Of the 11 patients, 4 were men and 7 were women. The location of the cancer was colorectal in 8 patients, pancreatic in 2 patients, and in the biliary tract in 1 patient. A total of 6 cases received adjuvant chemotherapy and 5 cases received treatment for recurrent or metastatic cancer. The chemotherapy regimens for colorectal cancer included FOLFIRI + bevacizumab for 3 patients, FOLFOX for 2 patients, FOLFOX + bevacizumab for 1 patient, FOLFIRI + panitumumab for 1 patient and TAS-102 for 1 patient. The chemotherapy regimens used for pancreatic cancer were S-1 and gemcitabine + nab-paclitaxel. The chemotherapy administered for biliary tract cancer was gemcitabine + cisplatin ([Table I](#tI-mco-0-0-1557){ref-type="table"}).

### Assessment of fatigue

The BFI scores for all patients in the present study are presented in [Fig. 1](#f1-mco-0-0-1557){ref-type="fig"}. In all the patients, the pre-treatment scores were significantly higher compared with the post-treatment scores (mean pre-BFI: 4.9±1.8 vs. post-BFI: 1.2±1.6; P\<0.0001). The mean ± SD changes in the BFI scores were −3.8±0.81 and −3.6±1.2 in the Adj. and Rec. groups, respectively. The difference in the mean change in the scores between the groups was −0.2 (not statistically significant). The mean ± SD BFI scores after treatment were 0.75±0.88 in the Adj. and 1.8±2.1 in the Rec. group.

### Nutritional assessment

The mean ± SD changes in the levels of albumin were 0.017±0.14 mg/dl in the Adj. group and −0.20±0.14 mg/dl in the Rec. group. The difference was not statistically significant in either group ([Fig. 2](#f2-mco-0-0-1557){ref-type="fig"}).

The mean ± SD lymphocyte counts in the Adj. group were 939.7±478.5/µl pre-treatment and 1,085.5±478.5/µl post-treatment. A total of 4 patients exhibited increased lymphocyte counts after treatment. The mean ± SD lymphocyte counts in the Rec. group were 1,291.6±637.7/µl pre-treatment and 1,169.2±554.0/µl post-treatment. The difference was not statistically significant in either group ([Fig. 3](#f3-mco-0-0-1557){ref-type="fig"}).

### Safety

According to the National Cancer Network-Common Terminology Criteria, no adverse events potentially associated with LC were reported for any patient during this study. Chemotherapy was well-tolerated by all patients during this study.

Discussion
==========

In the present study, hat LC supplementation reduced fatigue in all cancer patients. There was no significant difference in the mean change of BFI scores between the Adj. and Rec. groups. Based on these data, it may be suggested that chemotherapy-induced damage of the carnitine system and secondary deficiency of this molecule may cause fatigue due to impaired energy metabolism ([@b12-mco-0-0-1557],[@b13-mco-0-0-1557]). Thus, restoration of the carnitine pool may alleviate the fatigue of cancer patients ([@b14-mco-0-0-1557]). In the Rec. group, fatigue was still marked compared with the Adj. group after LC supplementation, as cytokine production from cancer cells and pro-inflammatory cytokines from cancer patients may also contribute to the fatigue ([@b15-mco-0-0-1557]). To the best of our knowledge, this is the first study to investigate therapeutic intervention with carnitine in the Adj. and Rec. patient groups. The results were encouraging, as LC supplementation reduced chemotherapy-induced fatigue in all patients who received this treatment.

Second, it was demonstrated that LC supplementation improved the nutritional status of the patients. In addition, all Adj. group patients continued chemotherapy sequentially, and did not require a reduction in the dose of the chemotherapy regimen. LC supplementation also leads to an improved nitrogen balance, either due to increased protein synthesis or abrogation of the inflammatory processes under pathological conditions, prevents oxidative stress, and improves mitochondrial function ([@b16-mco-0-0-1557]).

The beneficial effect of LC supplementation on mechanisms involved in skeletal muscle loss under pathological conditions may explain its anti-catabolic effects and/or the improvement of fatigue-related parameters following LC supplementation in patients with chronic kidney disease ([@b17-mco-0-0-1557]), cancer ([@b5-mco-0-0-1557],[@b9-mco-0-0-1557],[@b18-mco-0-0-1557],[@b19-mco-0-0-1557]), and hepatitis C and hepatic encephalopathy ([@b20-mco-0-0-1557]).

LC supplementation improved general fatigue in all cancer patients during chemotherapy. LC may improve the ability of cancer patients to cope with chemotherapy by reducing general fatigue and improving the nutritional status. The limitations of the present study included its design (single-institution, non-randomized study), the limited number of included patients, and the fact that carnitine levels in the plasma were not measured. Despite these limitations, our findings may provide evidence to support the efficacy of LC supplementation in controlling CRF. However, further research is required to confirm our findings. A randomized, double-blind, placebo-controlled trial is currently being planned to demonstrate the efficacy of LC supplementation, based on previously published LC supplementation articles ([@b18-mco-0-0-1557],[@b21-mco-0-0-1557]).
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###### 

Characteristics of the patients enrolled in the present study.

  Case no.   Age, years   Sex   Primary     Regimen                Adj. or Rec.
  ---------- ------------ ----- ----------- ---------------------- --------------------------
    1        73           M     Bile duct   GEM + CDDP             Adj.
    2        68           M     Rectum      FOLFOX                 Adj.
    3        69           F     Pancreas    TS-1                   Adj.
    4        52           F     Colon       FOLFOX                 Adj.
    5        65           F     Colon       FOLFIRI + Bmab         Adj.
    6        74           F     Rectum      FOLFIRI + Bmab         Adj.
    7        68           F     Pancreas    GEM + nab-paclitaxel   Rec. (bone)
    8        74           F     Colon       FOLFOX + Bmab          Rec. (liver)
    9        64           M     Colon       FOLFIRI + Pmab         Rec. (peritoneal)
  10         77           F     Colon       FOLFIRI + Bmab         Rec. (lung, peritoneal)
  11         59           M     Rectum      TAS-102                Rec. (liver, peritoneal)

Adj., adjuvant chemotherapy; Rec., recurrent or metastatic cancer; Bmab, bevacizumab; Pmab, panitumumab; M, male; F, female; GEM, gemcitabine; CDDP, cisplatin.
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